DarioHealth Corp. (DRIO)
USD 0.75
(3.79%)
USD 0.75
(3.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 20.35 Million USD | -26.41% |
| 2022 | 27.65 Million USD | 34.82% |
| 2021 | 20.51 Million USD | 170.76% |
| 2020 | 7.57 Million USD | 0.22% |
| 2019 | 7.55 Million USD | 2.23% |
| 2018 | 7.39 Million USD | 43.02% |
| 2017 | 5.17 Million USD | 84.45% |
| 2016 | 2.8 Million USD | 240.58% |
| 2015 | 823 Thousand USD | 1513.73% |
| 2014 | 51 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 6.25 Million USD | 8.63% |
| 2024 Q1 | 5.75 Million USD | 59.24% |
| 2023 FY | 20.35 Million USD | -26.41% |
| 2023 Q3 | 3.51 Million USD | -42.82% |
| 2023 Q2 | 6.15 Million USD | -12.94% |
| 2023 Q4 | 3.61 Million USD | 2.79% |
| 2023 Q1 | 7.06 Million USD | 3.77% |
| 2022 Q4 | 6.8 Million USD | 3.09% |
| 2022 Q3 | 6.6 Million USD | 6.83% |
| 2022 Q2 | 6.18 Million USD | -23.28% |
| 2022 Q1 | 8.05 Million USD | 33.69% |
| 2022 FY | 27.65 Million USD | 34.82% |
| 2021 FY | 20.51 Million USD | 170.76% |
| 2021 Q1 | 3.59 Million USD | 72.84% |
| 2021 Q2 | 5.26 Million USD | 46.34% |
| 2021 Q3 | 5.62 Million USD | 6.99% |
| 2021 Q4 | 6.02 Million USD | 7.09% |
| 2020 FY | 7.57 Million USD | 0.22% |
| 2020 Q1 | 1.66 Million USD | -7.29% |
| 2020 Q2 | 1.78 Million USD | 7.2% |
| 2020 Q4 | 2.08 Million USD | 1.86% |
| 2020 Q3 | 2.04 Million USD | 14.27% |
| 2019 Q2 | 1.65 Million USD | -26.36% |
| 2019 Q4 | 1.79 Million USD | -3.75% |
| 2019 FY | 7.55 Million USD | 2.23% |
| 2019 Q1 | 2.24 Million USD | 31.88% |
| 2019 Q3 | 1.86 Million USD | 13.14% |
| 2018 Q4 | 1.7 Million USD | -9.53% |
| 2018 Q2 | 2.05 Million USD | 17.26% |
| 2018 Q1 | 1.75 Million USD | 11.28% |
| 2018 FY | 7.39 Million USD | 43.02% |
| 2018 Q3 | 1.87 Million USD | -8.74% |
| 2017 FY | 5.17 Million USD | 84.45% |
| 2017 Q4 | 1.57 Million USD | 14.76% |
| 2017 Q3 | 1.37 Million USD | 13.64% |
| 2017 Q2 | 1.21 Million USD | 20.16% |
| 2017 Q1 | 1 Million USD | 20.17% |
| 2016 FY | 2.8 Million USD | 240.58% |
| 2016 Q1 | 568 Thousand USD | 84.42% |
| 2016 Q2 | 669 Thousand USD | 17.78% |
| 2016 Q3 | 728 Thousand USD | 8.82% |
| 2016 Q4 | 838 Thousand USD | 15.11% |
| 2015 Q4 | 308 Thousand USD | 12.82% |
| 2015 Q2 | 175 Thousand USD | 161.19% |
| 2015 Q1 | 67 Thousand USD | 31.37% |
| 2015 FY | 823 Thousand USD | 1513.73% |
| 2015 Q3 | 273 Thousand USD | 56.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | 51 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 51 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2001 Q2 | 5.26 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 34.872% |
| Biodesix, Inc. | 49.08 Million USD | 58.539% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -703.633% |
| Castle Biosciences, Inc. | 219.78 Million USD | 90.74% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.186% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.444% |
| Illumina, Inc. | 4.5 Billion USD | 99.548% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -554.031% |
| iSpecimen Inc. | 9.92 Million USD | -104.992% |
| Standard BioTools Inc. | 106.34 Million USD | 80.861% |
| 23andMe Holding Co. | 219.63 Million USD | 90.734% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 98.921% |
| NeoGenomics, Inc. | 591.64 Million USD | 96.56% |
| Inotiv, Inc. | 572.42 Million USD | 96.445% |
| Psychemedics Corporation | 22.09 Million USD | 7.901% |
| Prenetics Global Limited | 21.74 Million USD | 6.396% |
| Precipio, Inc. | 15.19 Million USD | -33.921% |
| RadNet, Inc. | 1.61 Billion USD | 98.741% |
| Sotera Health Company | 1.04 Billion USD | 98.06% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 55.549% |
| Exagen Inc. | 52.54 Million USD | 61.27% |
| Natera, Inc. | 1.08 Billion USD | 98.12% |
| Aspira Women's Health Inc. | 9.15 Million USD | -122.329% |
| Neogen Corporation | 924.22 Million USD | 97.798% |
| Myriad Genetics, Inc. | 678.4 Million USD | 97.0% |
| ICON Public Limited Company | 8.12 Billion USD | 99.749% |
| Bionano Genomics, Inc. | 36.11 Million USD | 43.648% |
| CareDx, Inc | 280.32 Million USD | 92.74% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | 93.497% |
| Guardant Health, Inc. | 563.94 Million USD | 96.391% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -108.294% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 92.963% |
| Sera Prognostics, Inc. | 306 Thousand USD | -6550.98% |
| OPKO Health, Inc. | 863.49 Million USD | 97.643% |
| Personalis, Inc. | 73.48 Million USD | 72.303% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -52.251% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 55.549% |
| MDxHealth SA | 70.19 Million USD | 71.006% |
| Prenetics Global Limited | 21.74 Million USD | 6.396% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -2172.75% |
| Trinity Biotech plc | 56.83 Million USD | 64.189% |
| Neuronetics, Inc. | 71.34 Million USD | 71.475% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -703.633% |